Satralizumab ELISA Kit

Catalog No.

KDC36902

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD126 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Satralizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Satralizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Satralizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Satralizumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.13 - 5,000 ng/mL

Sensitivity

33.50 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	1950.0	506.5	171.7	1874.0	520.7	158.1
Standard deviation	170.6	34.3	13.4	182.2	69.3	28.4
CV (%)	8.7	6.8	7.8	9.7	13.3	17.9

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

Sapelizumab, SA-237, SA237, satralizumab-mwg, CAS: 1535963-91-7

Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618

From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis., PMID:40447786

Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity., PMID:40403514

Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab., PMID:40324548

Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120

Potential drug targets for Neuromyelitis optica spectrum disorders (NMOSD): A Mendelian randomization analysis., PMID:40294019

Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics., PMID:40292035

Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data., PMID:40288333

Very-late-onset neuromyelitis optica spectrum disorder: a case report and review., PMID:40276466

Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative., PMID:40267692

Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG-Positive NMOSD., PMID:40257801

Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review., PMID:40203604

Satralizumab after inebilizumab treatment in a patient with recurrent neuromyelitis optica spectrum disorder: A case report., PMID:40193676

Ventral Subpial and Central Cord Enhancement in Spinal Neurosarcoidosis: The Reverse Trident Sign., PMID:40168633

Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series., PMID:40132364

Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea., PMID:40065454

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD., PMID:39932929

Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder., PMID:39913883

Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay., PMID:39901660

CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity., PMID:39869499

Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report., PMID:39867894

Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial., PMID:39862880

Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how., PMID:39861933

Curriculum Innovations: A Novel Neurology Clinician-Educator Program., PMID:39748890

[Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum disorders]., PMID:39731371

Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria., PMID:39708293

Case report: Satralizumab as an adjunctive therapy for AQP-4 antibody and MOG antibody dual-negative optic neuritis in a third-trimester pregnancy case., PMID:39687907

Case report: Satralizumab therapy for bilateral refractory optic neuritis following the first dose of bivalent human papilloma virus vaccine., PMID:39628490

Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan., PMID:39470886

An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder., PMID:39460545

Pediatric MOG-Ab-Associated Encephalitis: Supporting Early Recognition and Treatment., PMID:39393046

Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model., PMID:39380259

Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice., PMID:39321395

Intracranial Pressure Elevation and MOGAD., PMID:39283648

Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study., PMID:39278895

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms., PMID:39237493

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)., PMID:39193150

Visual improvement in a case of neuromyelitis optica spectrum disorder-related optic neuritis after 18 months of treatment with satralizumab: A case report., PMID:39157378

Dysthyroid Optic Neuropathy Complicated by Neuromyelitis Optica Spectrum Disorder: A Case Report., PMID:39144641

The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature., PMID:39110029

Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network., PMID:39099240

Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights., PMID:39031103

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance., PMID:39012406

Frequency of Asymptomatic Optic Nerve Enhancement in 203 Patients With MOG Antibody-Associated Disease., PMID:38924706

Interleukin-6 Signaling Blockade Induces Regulatory Plasmablasts in Neuromyelitis Optica Spectrum Disorder., PMID:38889374

Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder., PMID:38722571

MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use., PMID:38696737

[Novel immunomodulatory therapies in myasthenia gravis]., PMID:38665106

Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease., PMID:38628414

Document Download

Satralizumab ELISA Kit.pdf